Gioacchino Leandro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/777353/publications.pdf

Version: 2024-02-01

208 papers 15,584 citations

69 h-index 118 g-index

209 all docs

209 docs citations

times ranked

209

12522 citing authors

#	Article	IF	CITATIONS
1	Breath Tests for the Non-invasive Diagnosis of Small Intestinal Bacterial Overgrowth: A Systematic Review With Meta-analysis. Journal of Neurogastroenterology and Motility, 2020, 26, 16-28.	2.4	38
2	Trends in adherence to the Mediterranean diet in South Italy: A cross sectional study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 410-417.	2.6	39
3	NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with ⁹⁰ Y Resin Microspheres Versus Sorafenib in Advanced Hepatocellular Carcinoma. Journal of Nuclear Medicine, 2020, 61, 1736-1742.	5.0	27
4	Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2020, 52, 374-391.	0.9	29
5	Distinct associations of DSM-5 Somatic Symptom Disorder, the Diagnostic Criteria for Psychosomatic Research-Revised (DCPR-R) and symptom severity in patients with irritable bowel syndrome. General Hospital Psychiatry, 2020, 64, 56-62.	2.4	10
6	Hospital admission for digestive diseases: Gastroenterology units offer a more effective and efficient care. Digestive and Liver Disease, 2019, 51, 43-46.	0.9	3
7	Fatty liver and mortality: a cohort population study in South Italy. BMJ Open, 2019, 9, e027379.	1.9	6
8	Cardiovascular morbidity and mortality is increased postâ€liver transplantation even in recipients with no preâ€existing risk factors. Liver International, 2019, 39, 1557-1565.	3.9	18
9	Stomach-partitioning gastrojejunostomy is better than conventional gastrojejunostomy in palliative care of gastric outlet obstruction for gastric or pancreatic cancer: a meta-analysis. Journal of Gastrointestinal Oncology, 2019, 10, 283-291.	1.4	15
10	Collagen proportionate area is an independent predictor of longâ€term outcome in patients with nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 1214-1222.	3.7	55
11	Diagnosis of chronic anaemia in gastrointestinal disorders: A guideline by the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) and the Italian Society of Paediatric Gastroenterology Hepatology and Nutrition (SIGENP). Digestive and Liver Disease, 2019, 51, 471-483.	0.9	21
12	IBS clinical management in Italy: The AIGO survey. Digestive and Liver Disease, 2019, 51, 782-789.	0.9	19
13	Five common errors to avoid in clinical practice: the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) Choosing Wisely Campaign. Internal and Emergency Medicine, 2019, 14, 301-308.	2.0	6
14	Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors. Inflammatory Bowel Diseases, 2018, 24, 1589-1596.	1.9	58
15	Direct antiviral agents and risk of HCC: Waiting for Godot. Journal of Hepatology, 2018, 68, 614-616.	3.7	3
16	Probiotic monotherapy and <i>Helicobacter pylori </i> eradication: A systematic review with pooled-data analysis. World Journal of Gastroenterology, 2018, 24, 139-149.	3.3	78
17	Gender equality in medicine: What do gastroenterologists from Italy think of it?. Digestive and Liver Disease, 2018, 50, 725-727.	0.9	3
18	Management and prognosis of hepatocellular carcinoma in the elderly: Results of an inâ€field multicenter cohort study. Liver International, 2017, 37, 1184-1192.	3.9	15

#	Article	IF	CITATIONS
19	Meta-analysis of the impact of SPINK1 p.N34S gene variation in Caucasic patients with chronic pancreatitis. An update. Digestive and Liver Disease, 2017, 49, 847-853.	0.9	20
20	Nonâ€selective betaâ€blockers are not associated with increased mortality in cirrhotic patients with ascites. Liver International, 2017, 37, 1334-1344.	3.9	33
21	The role of alexithymia and gastrointestinal-specific anxiety as predictors of treatment outcome in irritable bowel syndrome. Comprehensive Psychiatry, 2017, 73, 127-135.	3.1	33
22	Low Alcohol and Cigarette Use Is Associated to the Risk of Developing Chronic Pancreatitis. Pancreas, 2017, 46, 225-229.	1.1	8
23	Evidence for the Presence of Non-Celiac Gluten Sensitivity in Patients with Functional Gastrointestinal Symptoms: Results from a Multicenter Randomized Double-Blind Placebo-Controlled Gluten Challenge. Nutrients, 2016, 8, 84.	4.1	155
24	Undernutrition, risk of malnutrition and obesity in gastroenterological patients: A multicenter study. World Journal of Gastrointestinal Oncology, 2016, 8, 563.	2.0	11
25	Genetic Associations of Alexithymia in Predicting Interferon-Induced Depression in Chronic Hepatitis C. Psychopathology, 2015, 48, 417-420.	1.5	7
26	A single-centre prospective, cohort study of the natural history of acute pancreatitis. Digestive and Liver Disease, 2015, 47, 205-210.	0.9	38
27	The role of alexithymia in quality of life impairment in patients with chronic hepatitis C during antiviral treatment. Comprehensive Psychiatry, 2015, 60, 17-25.	3.1	9
28	Open versus laparoscopic cholecystectomy in acute cholecystitis. Systematic review and meta-analysis. International Journal of Surgery, 2015, 18, 196-204.	2.7	252
29	Serotonin gene polymorphisms and lifetime mood disorders in predicting interferon-induced depression in chronic hepatitis C. Journal of Affective Disorders, 2015, 183, 90-97.	4.1	14
30	Confounders in the detection of minimal hepatic encephalopathy: a neuropsychological and quantified <scp>EEG</scp> study. Liver International, 2015, 35, 1524-1532.	3.9	19
31	Somatization Symptoms or Interferon-Related Adverse Events? Alexithymia and Somatization in Somatic Symptom Reporting of Patients with Chronic Hepatitis C. Psychotherapy and Psychosomatics, 2014, 83, 310-311.	8.8	8
32	White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths. Digestive and Liver Disease, 2014, 46, 579-589.	0.9	40
33	Alexithymia and gastrointestinal-specific anxiety in moderate to severe irritable bowel syndrome. Comprehensive Psychiatry, 2014, 55, 1647-1653.	3.1	35
34	How to interpret a randomized controlled study stopped early. Intensive Care Medicine, 2013, 39, 1642-1643.	8.2	5
35	Meta-Analysis of Bismuth Quadruple Therapy versus Clarithromycin Triple Therapy for Empiric Primary Treatment of Helicobacter pylori Infection. Digestion, 2013, 88, 33-45.	2.3	141
36	Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation. Journal of Hepatology, 2013, 58, 962-968.	3.7	56

#	Article	IF	Citations
37	Endoscopic ultrasonography versus endoscopic retrograde cholangiopancreatography in acute biliary pancreatitis. European Journal of Gastroenterology and Hepatology, 2011, 23, 367-374.	1.6	59
38	Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver International, 2011, 31, 730-739.	3.9	120
39	Natural History and Outcome of Hepatic Vascular Malformations in a Large Cohort of Patients with Hereditary Hemorrhagic Teleangiectasia. Digestive Diseases and Sciences, 2011, 56, 2166-2178.	2.3	106
40	Efficacy of 5-ASA in the Treatment of Colonic Diverticular Disease. Journal of Clinical Gastroenterology, 2010, 44, 113-119.	2.2	39
41	Terlipressin therapy for renal failure in cirrhosis. European Journal of Gastroenterology and Hepatology, 2010, 22, 481-486.	1.6	24
42	Multidimensional Prognostic Index Based on a Comprehensive Geriatric Assessment Predicts Short-Term Mortality in Older Patients With Heart Failure. Circulation: Heart Failure, 2010, 3, 14-20.	3.9	146
43	Connections Between Genetics and Clinical Data: Role of MCP-1, CFTR, and SPINK-1 in the Setting of Acute, Acute Recurrent, and Chronic Pancreatitis. American Journal of Gastroenterology, 2010, 105, 199-206.	0.4	61
44	Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection. Gastroenterology, 2010, 138, 116-122.	1.3	175
45	Sequential Therapy or Triple Therapy for Helicobacter pylori Infection. American Journal of Gastroenterology, 2009, 104, 3069-3079.	0.4	254
46	Contrast echocardiography for pulmonary arteriovenous malformations screening: does any bubble matter?. European Journal of Echocardiography, 2009, 10, 513-518.	2.3	79
47	The Multidimensional Prognostic Index Predicts Short- and Long-Term Mortality in Hospitalized Geriatric Patients With Pneumonia. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2009, 64A, 880-887.	3.6	78
48	Computer-assisted image analysis of liver collagen: Relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology, 2009, 49, 1236-1244.	7.3	248
49	TIPS for refractory ascites: a single-centre experience. Journal of Gastroenterology, 2009, 44, 1089-1095.	5.1	35
50	βâ€Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a metaâ€analysis. Liver International, 2009, 29, 1189-1193.	3.9	207
51	Acid-related disorders in the elderly. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2009, 23, 839-848.	2.4	53
52	Epidemiology of HCV Infection in the General Population: A Survey in a Southern Italian Town. American Journal of Gastroenterology, 2009, 104, 2740-2746.	0.4	77
53	Radiofrequency Thermal Ablation vs. Percutaneous Ethanol Injection for Small Hepatocellular Carcinoma in Cirrhosis: Meta-Analysis of Randomized Controlled Trials. American Journal of Gastroenterology, 2009, 104, 514-524.	0.4	239
54	Association of Apolipoprotein E and Angiotensin Converting Enzyme Gene Polymorphisms with the Multidimensional Impairment in Older Patients. Rejuvenation Research, 2009, 12, 239-247.	1.8	6

#	Article	IF	CITATIONS
55	Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. Liver International, 2008, 28, 370-376.	3.9	31
56	Efficacy of Loco-Regional Ablation Therapy of HCC in a Population of Liver Transplanted Patients. Digestive Diseases and Sciences, 2008, 53, 1131-1137.	2.3	11
57	Metaâ€analysis: the outcome of antiâ€viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Alimentary Pharmacology and Therapeutics, 2008, 28, 397-404.	3.7	104
58	Pegylatedâ€interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and metaâ€analysis of prospective controlled studies. Journal of Viral Hepatitis, 2008, 15, 699-709.	2.0	102
59	Development and Validation of a Multidimensional Prognostic Index for One-Year Mortality from Comprehensive Geriatric Assessment in Hospitalized Older Patients. Rejuvenation Research, 2008, 11, 151-161.	1.8	397
60	A comparison of kaolin-activated versus nonkaolin-activated thromboelastography in native and citrated blood. Blood Coagulation and Fibrinolysis, 2008, 19, 495-501.	1.0	28
61	Long-Term Outcome of Crohn's Disease Following Corticosteroid-Induced Remission. American Journal of Gastroenterology, 2007, 102, 814-819.	0.4	22
62	Quality of Life in Uncomplicated Symptomatic Diverticular Disease: Is It Another Good Reason for Treatment?. Digestive Diseases, 2007, 25, 252-259.	1.9	72
63	Usefulness of the Comprehensive Geriatric Assessment in Older Patients with Upper Gastrointestinal Bleeding: A Two-Year Follow-Up Study. Digestive Diseases, 2007, 25, 124-128.	1.9	35
64	Pancreatic Duct Stents in the Prophylaxis of Pancreatic Damage after Endoscopic Retrograde Cholangiopancreatography: A Systematic Analysis of Benefits and Associated Risks. Digestion, 2007, 75, 156-163.	2.3	84
65	Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study. Journal of Hepatology, 2007, 46, 206-212.	3.7	188
66	Bowel Obsession Syndrome in a Patient With Ulcerative Colitis. Psychosomatics, 2007, 48, 448-450.	2.5	13
67	Systematic Review of HVPG Measurement: Statistics Versus Clinical Applicability. Gastroenterology, 2007, 132, 1201-1202.	1.3	5
68	Genetic Susceptibility to Nonsteroidal Anti-Inflammatory Drug–Related Gastroduodenal Bleeding: Role of Cytochrome P450 2C9 Polymorphisms. Gastroenterology, 2007, 133, 465-471.	1.3	161
69	Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointestinal Endoscopy, 2007, 65, 624-632.	1.0	130
70	Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World Journal of Gastroenterology, 2007, 13, 4467.	3.3	19
71	Early versus late surgery for ileoâ€caecal Crohn's disease. Alimentary Pharmacology and Therapeutics, 2007, 26, 1303-1312.	3.7	90
72	Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C. Liver International, 2007, 27, 612-619.	3.9	30

#	Article	IF	Citations
73	A Curcuminâ€Based 1â€Week Triple Therapy for Eradication of <i>Helicobacter pylori</i> Infection: Something to Learn From Failure?. Helicobacter, 2007, 12, 238-243.	3.5	111
74	Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data. Gastroenterology, 2006, 130, 1636-1642.	1.3	517
75	Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis. Transplant Infectious Disease, 2006, 8, 3-12.	1.7	35
76	Clinical Features of Reflux Esophagitis in Older People: A Study of 840 Consecutive Patients. Journal of the American Geriatrics Society, 2006, 54, 1537-1542.	2.6	107
77	Risk factors, Sequential Organ Failure Assessment and Model for End-stage Liver Disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Alimentary Pharmacology and Therapeutics, 2006, 23, 883-893.	3.7	232
78	Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. Alimentary Pharmacology and Therapeutics, 2006, 23, 1235-1240.	3.7	43
79	Effects of interferon plus ribavirin treatment on NF- \hat{P} B, TGF- \hat{I}^2 1, and metalloproteinase activity in chronic hepatitis C. Modern Pathology, 2006, 19, 1047-1054.	5. 5	16
80	King's criteria, APACHE II, and SOFA scores in acute liver failure. Hepatology, 2006, 43, 881-881.	7.3	26
81	Effect of <i>Helicobacter pylori</i> Eradication on the Outcome of Reflux Esophagitis and Chronic Gastritis in the Elderly. Gerontology, 2006, 52, 99-106.	2.8	21
82	Transjugular liver biopsy: how good is it for accurate histological interpretation?. Gut, 2006, 55, 1789-1794.	12.1	109
83	Effects of chronic therapy with non-steroideal antinflammatory drugs on gastric permeability of sucrose: A study on 71 patients with rheumatoid arthritis. World Journal of Gastroenterology, 2006, 12, 5017.	3.3	3
84	Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis. World Journal of Gastroenterology, 2006, 12, 7821.	3.3	48
85	Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. European Journal of Gastroenterology and Hepatology, 2005, 17, 745-751.	1.6	81
86	Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels. Fundamental and Clinical Pharmacology, 2005, 19, 497-501.	1.9	28
87	Primary prophylaxis of variceal bleeding in cirrhotics unable to take beta-blockers: a randomized trial of ligation. Alimentary Pharmacology and Therapeutics, 2005, 21, 1435-1443.	3.7	53
88	Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transplantation, 2005, 11, 386-395.	2.4	95
89	Efficacy of Mesalazine in the Treatment of Symptomatic Diverticular Disease. Digestive Diseases and Sciences, 2005, 50, 581-586.	2.3	102
90	Treatment Effects of Partially Hydrolyzed Guar Gum on Symptoms and Quality of Life of Patients with Irritable Bowel Syndrome. A Multicenter Randomized Open Trial. Digestive Diseases and Sciences, 2005, 50, 1107-1112.	2.3	43

#	Article	IF	Citations
91	Natural Course of Functional Dyspepsia After Helicobacter pyloriEradication: A Seven-Year Survey. Digestive Diseases and Sciences, 2005, 50, 2286-2295.	2.3	16
92	Endoscopic Treatment of Gastroesophageal Reflux Disease. Endoscopy, 2005, 37, 470-478.	1.8	10
93	Reply to Dr. Barkun's Letter. American Journal of Gastroenterology, 2005, 100, 2133-2134.	0.4	2
94	External Validation of Biochemical Indices for Noninvasive Evaluation of Liver Fibrosis in HCV Chronic Hepatitis. American Journal of Gastroenterology, 2005, 100, 868-873.	0.4	34
95	Monitoring surgical and medical outcomes: the Bernoulli cumulative SUM chart. A novel application to assess clinical interventions. Postgraduate Medical Journal, 2005, 81, 647-652.	1.8	33
96	Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. Journal of Hepatology, 2005, 42, 41-46.	3.7	151
97	Assessment of the agreement between wedge hepatic vein pressure and portal vein pressure in cirrhotic patients. Digestive and Liver Disease, 2005, 37, 601-608.	0.9	82
98	Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding. Annals of Internal Medicine, 2004, 141, 78.	3.9	4
99	Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut, 2004, 53, 406-412.	12.1	246
100	Clinical Usefulness of Serum Pepsinogen II in the Management of <i>Helicobacter pylori</i> Infection. Digestion, 2004, 70, 167-172.	2.3	21
101	Helicobacter pylori infection and the risk of gastro-duodenal damage in symptomatic elderly chronic low-dose aspirin users: effect of antisecretory drugs. Age and Ageing, 2004, 33, 402-404.	1.6	8
102	Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study. Alimentary Pharmacology and Therapeutics, 2004, 19, 331-337.	3.7	10
103	Protonâ€pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/nonâ€steroidal antiâ€nflammatory drugs. Alimentary Pharmacology and Therapeutics, 2004, 20, 1091-1097.	3.7	70
104	Treatment of patients with HCV infection with or without liver biopsy. Journal of Viral Hepatitis, 2004, 11, 536-542.	2.0	19
105	Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin. Digestive and Liver Disease, 2004, 36, 666-670.	0.9	36
106	Combination therapy with amantadine and interferon in naıÌ^ve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. Journal of Hepatology, 2004, 40, 478-483.	3.7	38
107	Thromboelastography with citrated blood. Blood Coagulation and Fibrinolysis, 2004, 15, 103-107.	1.0	102
108	Role of endogenous endothelin-1 in ethanol-induced gastric mucosal damage in humans. Digestive Diseases and Sciences, 2003, 48, 663-669.	2.3	9

#	Article	IF	Citations
109	Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients. Journal of Gastroenterology and Hepatology (Australia), 2003, 14, 468-475.	2.8	35
110	Rabeprazole in a one-week eradication therapy of Helicobacter pylori: Comparison of different dosages. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 783-786.	2.8	8
111	Short†and longâ€term therapy for reflux oesophagitis in the elderly: a multiâ€centre, placeboâ€controlled study with pantoprazole. Alimentary Pharmacology and Therapeutics, 2003, 17, 1399-1406.	3.7	43
112	Small intestinal bacterial overgrowth and irritable bowel syndrome. American Journal of Gastroenterology, 2003, 98, 2572.	0.4	17
113	Natural course of acute hepatitis C: a long-term prospective study. Digestive and Liver Disease, 2003, 35, 104-113.	0.9	93
114	Dyspepsia and Helicobacter pylori infection: a prospective multicentre observational study. Digestive and Liver Disease, 2003, 35, 157-164.	0.9	15
115	Use of bovine lactoferrin for Helicobacter pylori eradication. Digestive and Liver Disease, 2003, 35, 706-710.	0.9	72
116	Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. Journal of Hepatology, 2003, 39, 239-244.	3.7	806
117	The risk of upper gastrointestinal bleeding in elderly users of aspirin and other non-steroidal antiinflammatory drugs: The role of gastroprotective drugs. Aging Clinical and Experimental Research, 2003, 15, 494-499.	2.9	55
118	NSAID and Aspirin Use by the Elderly in General Practice. Drugs and Aging, 2003, 20, 701-710.	2.7	82
119	â€~Serological biopsy' in firstâ€degree relatives of patients with gastric cancer affected by Helicobacter pylori infection. Scandinavian Journal of Gastroenterology, 2003, 38, 1223-1227.	1.5	37
120	The long term outcome of gastric non-invasive neoplasia. Gut, 2003, 52, 1111-1116.	12.1	167
121	Atrophic gastritis: pathology and endoscopy in the reversibility assessment. Gut, 2003, 52, 1387-a-1388.	12.1	24
122	Effect of Helicobacter pylori eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects. Gut, 2003, 52, 1543-1547.	12.1	28
123	Fibrosis in Chronic Hepatitis C Acquired in Infancy: Is It Only a Matter of Time?. American Journal of Gastroenterology, 2003, 98, 660-663.	0.4	121
124	Use of Lactoferrin for Helicobacter pylori Eradication. Journal of Clinical Gastroenterology, 2003, 36, 396-398.	2.2	35
125	Alexithymia as Predictor of Treatment Outcome in Patients with Functional Gastrointestinal Disorders. Psychosomatic Medicine, 2003, 65, 911-918.	2.0	124
126	Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut, 2002, 50, 697-700.	12.1	65

#	Article	IF	CITATIONS
127	Long-Term Clinical Outcome of Elderly Patients With Reflux Esophagitis: A Six-Month to Three-Year Follow-up Study. American Journal of Therapeutics, 2002, 9, 295-300.	0.9	27
128	Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. Journal of Hepatology, 2002, 36, 263-270.	3.7	290
129	Influence of Helicobacter pylori infection on severity of oesophagitis and response to therapy in the elderly. Digestive and Liver Disease, 2002, 34, 328-331.	0.9	19
130	Liver transplantation: the Italian experience. Digestive and Liver Disease, 2002, 34, 640-648.	0.9	37
131	The Italian experience on paediatric liver transplantation: 1988–1999 report. Digestive and Liver Disease, 2002, 34, 649-655.	0.9	1
132	Long-term follow-up of achalasia patients treated with botulinum toxin. Digestive and Liver Disease, 2002, 34, 105-110.	0.9	95
133	Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: A multicenter, placebo-controlled, randomized clinical trial. Gastrointestinal Endoscopy, 2002, 56, 488-495.	1.0	151
134	Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. Journal of Hepatology, 2002, 36, 799-804.	3.7	96
135	High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. Journal of Hepatology, 2002, 37, 109-116.	3.7	21
136	Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Alimentary Pharmacology and Therapeutics, 2002, 16, 1249-1259.	3.7	306
137	High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolyzed guar gum (PHGG). Digestive Diseases and Sciences, 2002, 47, 1697-1704.	2.3	86
138	Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: A multicenter, placebo-controlled, randomized clinical trial. Gastrointestinal Endoscopy, 2002, 56, 488-495.	1.0	134
139	Efficacy of 5 MU of interferon in combination with ribavirin for naıÌ've patients with chronic hepatitis C virus: a randomized controlled trial. Journal of Hepatology, 2001, 34, 441-446.	3.7	27
140	Ursodeooxycholic acid for primary biliary cirrhosis. Journal of Hepatology, 2001, 34, 352-353.	3.7	8
141	Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. Alimentary Pharmacology and Therapeutics, 2001, 15, 1031-1036.	3.7	24
142	Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology, 2001, 39, 119-124.	2.9	113
143	Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection: an AIGO study. Digestive Diseases and Sciences, 2001, 46, 1409-1415.	2.3	23
144	Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. Digestive Diseases and Sciences, 2001, 46, 1924-1936.	2.3	39

#	Article	IF	CITATIONS
145	A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology, 2001, 33, 989-993.	7.3	48
146	IN VITRO EFFECTS OF NALOXONE ON T-LYMPHOCYTE-DEPENDENT ANTIBACTERIAL ACTIVITY IN HEPATITIS C VIRUS (HCV) INFECTED PATIENTS AND IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS. Immunopharmacology and Immunotoxicology, 2001, 23, 1-11.	2.4	9
147	Gastric Dysplasia. American Journal of Surgical Pathology, 2000, 24, 167-176.	3.7	343
148	Long-term follow-up of achalasic patients treated with botulinum toxin. Ecological Management and Restoration, 2000, 13, 96-101.	0.4	18
149	Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. Alimentary Pharmacology and Therapeutics, 2000, 14, 1077-1082.	3.7	49
150	Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Digestive Diseases and Sciences, 2000, 45, 68-76.	2.3	188
151	Topographic patterns of intestinal metaplasia and gastric cancer. American Journal of Gastroenterology, 2000, 95, 1431-1438.	0.4	221
152	A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. Gut, 2000, 46, 597-600.	12.1	204
153	Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointestinal Endoscopy, 2000, 51, 1-7.	1.0	199
154	Antibody response to Helicobacter pylori CagA and heat-shock proteins in determining the risk of gastric cancer development. Digestive and Liver Disease, 2000, 32, 378-383.	0.9	19
155	Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study. Digestive and Liver Disease, 2000, 32, 667-672.	0.9	56
156	Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. Digestive and Liver Disease, 2000, 32, 763-768.	0.9	80
157	Cure of Helicobacter pylori-positive active duodenal ulcer patients: double-blind, multicentre, 12-month study comparing a two-week dual vs a one-week triple therapy. Digestive and Liver Disease, 2000, 32, 108-115.	0.9	10
158	The impact of previous HBV infection on the course of chronic hepatitis C. American Journal of Gastroenterology, 2000, 95, 3529-3536.	0.4	57
159	Helicobacter pylori infection in elderly patients with peptic ulcer. Age and Ageing, 1999, 28, 412-414.	1.6	9
160	Lack of association between Helicobacter pylori infection and extracardiac atherosclerosis in dyspeptic elderly subjects. Age and Ageing, 1999, 28, 367-371.	1.6	19
161	The effect of antibiotic resistance on the outcome of three 1â€week triple therapies against <i>Helicobacter pylori</i> . Alimentary Pharmacology and Therapeutics, 1999, 13, 667-673.	3.7	61
162	Semiquantitative assessment of IgM antibody to hepatitis B core antigen and prediction of the severity of chronic hepatitis B. Journal of Viral Hepatitis, 1999, 6, 429-434.	2.0	12

#	Article	IF	Citations
163	Prediction of relapse or sustained response in biochemical responders by serum hepatitis C virus RNA monitoring during interferon therapy. Journal of Viral Hepatitis, 1999, 6, 373-380.	2.0	0
164	High prevalence of Helicobacter pylori infection in shepherds. Digestive Diseases and Sciences, 1999, 44, 1161-1164.	2.3	70
165	Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. Hepatology, 1999, 30, 612-622.	7.3	320
166	Patients younger than 40 years with gastric carcinoma. Cancer, 1999, 85, 2506-2511.	4.1	74
167	Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet, The, 1999, 354, 1053-1060.	13.7	296
168	Intrafamilial transmission of hepatitis delta virus: molecular evidence. Journal of Hepatology, 1999, 30, 564-569.	3.7	66
169	The dark side of the gastric biopsy. Human Pathology, 1999, 30, 741-744.	2.0	14
170	Patients younger than 40 years with gastric carcinoma. Cancer, 1999, 85, 2506-2511.	4.1	7
171	Optimal PPIâ€based Triple Therapy for the Cure of Helicobacter pylori Infection: A Single Center Comparison of Four 14â€day Schedules. Helicobacter, 1998, 3, 115-119.	3.5	4
172	Intrasphincteric injection of botulinum toxin is effective in long-term treatment of esophageal achalasia., 1998, 21, 1540-1542.		64
173	Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Alimentary Pharmacology and Therapeutics, 1998, 12, 237-245.	3.7	96
174	Chronic hepatitis C in children: The pathological and clinical spectrum. Gastroenterology, 1998, 115, 1525-1529.	1.3	160
175	Functional Gastrointestinal Disorders and Eating Disorders: Relevance of the Association in Clinical Management. Scandinavian Journal of Gastroenterology, 1998, 33, 577-582.	1.5	56
176	The Long-Term Clinical Outcome of Elderly Patients with Helicobacter pylori-Associated Peptic Ulcer Disease. Gerontology, 1998, 44, 153-158.	2.8	37
177	The sup 13 /sup C-urea breath test as a predictor of intragastric bacterial load and severity of intragastric bacterial load and severity of interesting the strain of Clinical and Laboratory Investigation, 1998, 58, 19-28.	1.2	88
178	Hepatoblastoma: DNA nuclear content, proliferative indices, and pathology. Liver, 1998, 18, 128-133.	0.1	24
179	Cytotoxin-Associated Gene A-PositiveHelicobacter pylori Infection in the Elderly. Journal of Clinical Gastroenterology, 1998, 26, 18-22.	2.2	26
180	The effect of Helicobacter pylori infection on NSAID-related gastroduodenal damage in the elderly. European Journal of Gastroenterology and Hepatology, 1997, 9, 951-956.	1.6	65

#	Article	IF	Citations
181	Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly: a case-control study. Digestive Diseases and Sciences, 1997, 42, 586-591.	2.3	84
182	Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study. Hepatology, 1997, 25, 754-758.	7. 3	329
183	Hepatic stellate cell immunodetection and cirrhotic evolution of viral hepatitis in liver allografts. Hepatology, 1997, 26, 310-314.	7.3	48
184	Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone―for the evaluation of "borderline―values. Journal of Hepatology, 1996, 25, 644-648.	3.7	39
185	Antagonism to calcium antagonists. Lancet, The, 1996, 347, 1761-1762.	13.7	13
186	Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. Journal of Hepatology, 1996, 24, 301-307.	3.7	78
187	Omeprazole in the maintenance treatment of duodenal ulcer: results after 6 months of 20 mg daily, 20 mg every other day, or 40 mg on weekends. Current Therapeutic Research, 1996, 57, 33-41.	1.2	1
188	The Clinical Usefulness of Serum Pepsinogens, Specific IgG Antiâ€HP Antibodies and Gastrin for Monitoring ⟨i⟩Helicobacter pylori⟨i⟩ Treatment in Older People. Journal of the American Geriatrics Society, 1996, 44, 665-670.	2.6	24
189	Do concomitant diseases and therapies affect the persistence of ulcer symptoms in the elderly?. Digestive Diseases and Sciences, 1996, 41, 17-21.	2.3	10
190	Short-term treatment of gastric ulcer. Digestive Diseases and Sciences, 1996, 41, 1108-1131.	2.3	18
191	Helicobacter pylori in promotion of gastric carcinogenesis. Digestive Diseases and Sciences, 1996, 41, 950-955.	2.3	61
192	Nuclear DNA content and pathology in radically treated pancreatic carcinoma: The prognostic significance of DNA ploidy, histology and nuclear grade., 1996, 77, 459-466.		12
193	Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. Alimentary Pharmacology and Therapeutics, 1996, 10, 1021-1027.	3.7	43
194	Hepatitis C virus serotypes and liver pathology. Liver, 1996, 16, 353-357.	0.1	10
195	Gastric epithelial dysplasia. How clinicopathologic background relates to management. Cancer, 1995, 76, 376-382.	4.1	67
196	A Comparison of Five Maintenance Therapies for Reflux Esophagitis. New England Journal of Medicine, 1995, 333, 1106-1110.	27.0	542
197	Serum pepsinogens as markers of Helicobacter pylori eradication. Current Therapeutic Research, 1995, 56, 777-786.	1.2	4
198	The fluctuations of hepatitis C virus RNA and IgM anti-HCV (core) serum levels correlate with those of alanine aminotransferases during the hepatitis relapses of patients treated with interferon. Journal of Viral Hepatitis, 1995, 2, 171-174.	2.0	11

#	Article	IF	CITATIONS
199	Pepsin concentration in gastroduodenal biopsy homogenates in chronic ulcer disease. Digestive Diseases and Sciences, 1994, 39, 301-308.	2.3	3
200	Gastric epithelial dysplasia in the natural history of gastric cancer: A multicenter prospective follow-up study. Gastroenterology, 1994, 107, 1288-1296.	1.3	240
201	Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations. Liver, 1994, 14, 175-181.	0.1	57
202	Correspondence. Cancer, 1993, 71, 510-511.	4.1	5
203	Markers of slow-healing peptic ulcer in the elderly. Digestive Diseases and Sciences, 1993, 38, 1414-1421.	2.3	6
204	Malignant ascites. European Journal of Gastroenterology and Hepatology, 1993, 5, 251-256.	1.6	1
205	Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis. Cancer, 1991, 68, 1795-1798.	4.1	21
206	Predictive model of response to therapy with interferon in patients with chronic hepatitis B virus infection: A methodological note. Hepatology, 1990, 12, 180-181.	7.3	2
207	\hat{l}_{\pm} -Fetoprotein, tissue polypeptide antigen and ferritin in diagnosing primary hepatocellular carcinoma in patients with liver cirrhosis. Journal of Cancer Research and Clinical Oncology, 1989, 115, 276-278.	2.5	6
208	Ulcerative Colitis in Remission: Is It Possible to Predict the Risk of Relapse?. Digestion, 1989, 44, 217-221.	2.3	39